SCHEMBL10105558

SCHEMBL10105558

CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(F)c(C)c3)c(F)c2)ccn1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 10/20 0.71
RAF1 P04049 8/20 0.71
BRAF P15056 6/20 0.71
ABL1 P00519 5/20 0.71
RET P07949 5/20 0.71
MAPK14 Q16539 5/20 0.71
EPHX2 P34913 4/20 0.71
MAP3K20 Q9NYL2 4/20 0.71
RIPK2 O43353 3/20 0.71
EPHA2 P29317 3/20 0.71
KIT P10721 3/20 0.71
FGFR1 P11362 3/20 0.71
PDGFRA P16234 3/20 0.71
FLT1 P17948 3/20 0.71
EPHA1 P21709 3/20 0.71
TTK P33981 3/20 0.71
FLT4 P35916 3/20 0.71
FLT3 P36888 3/20 0.71
CLK1 P49759 3/20 0.71
LIMK1 P53667 3/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10105553 0.92 RAF1 (0.79) KDRRAF1BRAFABL1RET
SCHEMBL10105567 0.92 RAF1 (0.68) KDRRAF1BRAFABL1RET
SCHEMBL14911164 0.90 ABL1 (0.73) KDRRAF1BRAFABL1RET
SCHEMBL19888727 0.89 RAF1 (0.75) KDRRAF1BRAFABL1RET
SCHEMBL10105560 0.89 RAF1 (0.65) KDRRAF1BRAFABL1RET
SCHEMBL19878466 0.89 RAF1 (0.72) KDRRAF1BRAFABL1RET
SCHEMBL17433342 0.88 KDR (0.82) KDRRAF1BRAFABL1RET
SCHEMBL5080020 0.88 KDR (0.85) KDRRAF1BRAFABL1RET
SCHEMBL6473839 0.87 RAF1 (0.70) KDRRAF1BRAFABL1RET
SCHEMBL10105557 0.87 KDR (0.68) KDRRAF1BRAFABL1RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120077851-A1 Urea Derivatives as Kinase Inhibitors MEDOLUTION LIMITED (US) 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077851-A1 Urea Derivatives as Kinase Inhibitors MAP3K20, CDK20, MAP3K10 KDR 1768/4885RAF1 15/4885BRAF 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.